Compass Therapeutics Inc CMPX

$0.86 -0.04 (-4.93%)

Valuation

Market cap
154,281,000
Revenue TTM
$0
Net income TTM
$-66,490,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
20,754,201
Avg volume
4,247,638
Day's range
$0.83 – $0.98
Shares out
180,088,000
Stochastic %K
4%
Beta
1.02
Analysts
Strong Sell
Price target
$7.23

Price

Company profile

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. I...

Show more

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 500 8099
Website
https://www.compasstherapeutics.com
Address
80 Guest Street, Suite 601, Boston, United States

Latest news

Stocktwits

NFA_DYOR Oct 2, 11:48 PM
$CMPX You are 100% correct, and the data proves it. - On 9/30, the first 20,000 block of $1 puts hit the tape listed as "Between the market" at the midpoint. - But on 10/2, the data cleared and showed over 10,000 of those contracts shifted directly to "Bid or below." And 10,000 mid Forcing a massive block through at the bid means aggressive institutional selling, not buying. This whale sold 40,000 total puts across both days to pocket instant cash because they are confident the stock holds above $1 through 2027. You called it perfectly. When an institutional trader wants to buy protection because they think a stock will crash, they buy at the Ask price. When they want to dump options to collect cash upfront, they force the trade through at the Bid price. By looking at both days together, we see that what started as a mysterious middle-market trade on 9/30 cleared on 10/2 as an aggressive "Bid" sell order. The whale pocketed millions in cash upfront. The Jan put Break even $0.67
0 replies
Evaluwait Oct 2, 9:37 PM
$CMPX Any one else that bought today thinks the bought at less than cash value and significantly less than liquidation value. I believe cash and 10726 alone are worth more than $1.70 per share. Not for the feint of heart but my best purchases ever (ENPH and AEHR) were at low single digit prices when others only so complete failure. Not investment advice and bet only what you can afford to lose in any biotech microcap.
1 replies
bears_blood1 Oct 2, 8:35 PM
$CMPX please enlighten us because i am so eager to obliterate you. Someone posted tovicomig is working well, ctx are doing well, they have cash. For your info you only get notice of de listing if traded under $1. for 30 days, and you get 6 months to fix it.
2 replies
Vladxccc Oct 2, 8:24 PM
$CMPX More bad news and this can RS ?
3 replies
1nceagain Oct 2, 8:01 PM
$CMPX Watta friggin mental workout!
1 replies
bears_blood1 Oct 2, 7:11 PM 0 replies
bears_blood1 Oct 2, 7:08 PM 0 replies
bears_blood1 Oct 2, 7:08 PM
$CMPX buy buy buy. Volume massive with side ways this will rock
0 replies